StockData
Ascendis Pharma A/S logo

Ascendis Pharma A/S (ASND) stock

ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)

Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –

Ascendis Pharma A/S gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Ascendis Pharma A/S's gross profit for the twelve months ending Jun 30, 2026 was €955.90M, up 129.5% year over year. For fiscal 2025 it was €625.22M, up 95.8% from the year before. The highest annual figure on record is €625.22M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025€625.22M+95.8%
FY2024Dec 31, 2024€319.38M+43.7%
FY2023Dec 31, 2023€222.32M+469.5%
FY2022Dec 31, 2022€39.04M+817.4%
FY2021Dec 31, 2021€4.26M-38.8%
FY2020Dec 31, 2020€6.95M-48.0%
FY2019Dec 31, 2019€13.38M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€311.63M+146.2%
Q1 FY2026Mar 31, 2026€229.09M+174.6%
Q4 FY2025Dec 31, 2025€223.90M+40.0%
Q3 FY2025Sep 30, 2025€191.28M+310.2%
Q2 FY2025Jun 30, 2025€126.60M+416.0%
Q1 FY2025Mar 31, 2025€83.44M-5.5%
Q4 FY2024Dec 31, 2024€159.89M+35.2%
Q3 FY2024Sep 30, 2024€46.63M+14.7%
Q2 FY2024Jun 30, 2024€24.53M-28.8%
Q1 FY2024Mar 31, 2024€88.33M+204.9%
Q4 FY2023Dec 31, 2023€118.25M+564.9%
Q3 FY2023Sep 30, 2023€40.65M+198.9%
Q2 FY2023Jun 30, 2023€34.46M+579.2%
Q1 FY2023Mar 31, 2023€28.97M+1021.9%
Q4 FY2022Dec 31, 2022€17.78M+1194.3%
Q3 FY2022Sep 30, 2022€13.60M+1121.7%
Q2 FY2022Jun 30, 2022€5.07M+396.5%
Q1 FY2022Mar 31, 2022€2.58M+246.1%
Q4 FY2021Dec 31, 2021€1.37M–
Q3 FY2021Sep 30, 2021€1.11M–
Q2 FY2021Jun 30, 2021€1.02M–
Q1 FY2021Mar 31, 2021€746.00K–

More Ascendis Pharma A/S figures

See a number that looks wrong?